)
)
)
Up Next: M&A and Licensing in the Year Ahead?
While deal volumes have adjusted following the influx of capital during the pandemic, there has still been significant activity as pharma continues to assess overall strategy and biotech companies seek partners to continue progress in the clinic with the goal of commercialization. An overview presentation on deal trends will open this discussion, followed by pharma BD leaders and biotech companies that have partnered with them to offer perspective on navigating the complexities of dealmaking.